Skip to main content
Premium Trial:

Request an Annual Quote

Iconix Inks Biomarker Research Deal with Brigham and Women s Hospital Researcher

NEW YORK, Sept. 20 (GenomeWeb News) - Iconix Pharmaceuticals said today that it has signed an agreement to work with Roderick Jensen, acting director of the biotechnology center and laboratory for functional genomics at the Brigham and Women's Hospital, on the study and validation of gene expression patterns in patients with neurological diseases.

 

According to Iconix, Jensen's lab has developed a high-throughput validation strategy that uses multiple gene expression platforms to assay tissue samples. The partnership aims to validate gene expression changes in human peripheral blood for diagnostics, prognostics, and drug response. Jensen's strategy, Iconix said, will be tested in patients with Parkinson's disease.

 

In March, at the 43rd Annual Society of Toxicology Meeting in Baltimore, Md., Iconix said that it would publicly release a subset of its proprietary genomic biomarker data to researchers who agree to make their findings public.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.